Leaders at the Food and Drug Administration heard mixed feedback on a speedy drug review program initiated by former commissioner Marty Makary. While some praised its efficiency, many called for a pause and a return to standard procedures.
Leaders at the Food and Drug Administration (FDA) convened a listening session on Thursday to address criticisms and suggestions regarding a controversial voucher program introduced by former FDA Commissioner Marty Makary. The program, known as the Commissioner's National Priority Voucher, offered expedited one-to-two-month reviews for drugs deemed to align with national priorities such as addressing health crises and delivering innovative cures.
The session, held at the FDA’s White Oak Campus, featured 17 speakers from various backgrounds including patient groups, drug companies, and academic organizations. While some stakeholders expressed positive feedback, particularly those whose drugs had already benefited from the program, the majority urged the agency to pause the initiative and reintroduce it through standard regulatory procedures that require public input.
Makary launched the voucher program about a year ago, aiming to accelerate the review process for critical medications. However, critics raised concerns about potential political interference due to the vague nature of the prioritized criteria. Many participants at the session echoed these worries, emphasizing the need for transparency and public engagement in any future reforms.
The diverse perspectives highlighted during the meeting underscored the complex challenges faced by regulatory agencies when implementing expedited review programs. As the FDA considers next steps, stakeholders will likely continue to advocate for policies that balance speed with fairness and public trust.
